Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Average Target Price of $13.50

Vanda Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Vanda Pharmaceuticals a “Moderate Buy” consensus: six of nine analysts rate it a buy, two a hold, and one a sell; the average 12-month price target is $13.50.
  • Shares opened at $3.44, near the company’s 12-month low of $3.41, and below both its 50-day and 200-day moving averages.
  • Vanda reported a quarterly loss of $0.37 per share, beating the $0.68 loss analysts expected; revenue of $69.81 million also topped estimates. Institutional investors and hedge funds own 88.14% of shares.
  • Five stocks to consider instead of Vanda Pharmaceuticals.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $13.50.

VNDA has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating on shares of Vanda Pharmaceuticals in a research report on Monday, November 2nd. Zacks Research upgraded Vanda Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Wednesday, November 4th. Wall Street Zen raised Vanda Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, October 31st. B. Riley Financial reiterated a "buy" rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Finally, Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective for the company.

View Our Latest Analysis on VNDA

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $3.44 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $208.02 million, a price-to-earnings ratio of -0.74 and a beta of 0.74. The firm has a 50-day moving average of $4.34 and a two-hundred day moving average of $5.92. Vanda Pharmaceuticals has a twelve month low of $3.41 and a twelve month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.31. The firm had revenue of $69.81 million during the quarter, compared to analysts' expectations of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. As a group, analysts expect that Vanda Pharmaceuticals will post -2.53 earnings per share for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Large investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth about $29,000. Legal & General Group Plc bought a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $34,000. Allworth Financial LP acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $43,000. Walleye Capital LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $76,000. Finally, Royce & Associates LP bought a new position in Vanda Pharmaceuticals during the 3rd quarter worth approximately $65,000. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003. Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.

See Also

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vanda Pharmaceuticals Right Now?

Before you consider Vanda Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.

While Vanda Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines